##  [Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease](/us-en/news/media-releases/novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-prevention-vaso-occlusive-crises-sickle-cell-disease-0 "Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease") 

  Jan 08, 2019